"We will quickly integrate PBR to better serve our biotech and pharmaceutical clients earlier in the drug development cycle, providing high-end first-in-man clinical services as part of our global platform. We continue to take steps to execute PRA's growth strategies of expanded service offerings and geographic reach, with our recent expansion into India being another example."
PRA executives expects the acquisition to boost their service offerings to pharma and biotech companies for the clinical development of their drug candidates. The deal is expected to close in the third quarter.
More details on the integration of PBR into PRA's operations from PRA news release.
Comment Preview